

**Original Research Article****Seroprevalence of anti-mannose binding lectin autoantibodies in patients with rheumatoid arthritis in Sana'a city- Yemen****Abstract**

Rheumatoid arthritis (RA) characterized by synovial inflammation and destruction of cartilage and bone. Until now there is no single test that diagnoses RA, however, several blood tests may suggest the presence of this disease. RA is associated with the presence of a number of autoantibodies as such as rheumatoid factor (RF), anti-cyclic citrullinated peptide (ACPA) and anti-mannose binding lectin (anti-MBL).

This study aimed firstly to investigate the presence of anti-MBL autoantibodies in the sera of RA patients and healthy controls and secondly to determine the diagnostic value of this marker in comparison with the classical RF, C- reactive protein (CRP) and ACPA among RA cases.

This case-control study was conducted at four health establishments; two public (Al-Thawra Modern General Hospital and National Center of Central Public Health Laboratories) and two private (University of Science and Technology Hospital and Aulqi Specialized Medical Laboratories) in Sana'a city.

Ninety-four individuals were enrolled in this study. Forty-seven persons were clinically diagnosed to have RA by a rheumatologist and 47 healthy subjects without RA were used as controls. Sera were separated and tested for presence of serum anti-MBL autoantibodies, ACPA, RF and CRP by a commercially available enzyme linked immunosorbent assay (ELISA) and latex agglutination technique.

Study results showed that the mean $\pm$ SD for the levels of serum anti-MBL autoantibodies among RA cases were 394 $\pm$ 243 ng/ml which were significantly higher than that recorded among healthy controls (217 $\pm$ 173 ng/ml). The levels of serum anti-MBL autoantibodies were associated with positive RF and CRP tests ( $p=.02$  &  $.007$  respectively), but not with positive ACPA test ( $p=.42$ ).

The result of this study showed higher levels of serum anti-MBL autoantibodies among RA cases comparing with the healthy controls and reveal an association with positive results for RF and CRP, but not with ACPA. Therefore, the anti-MBL antibody levels may associated with systemic autoimmune diseases and might not exclusive to RA.

**Key words**

Rheumatoid arthritis; anti-MBL autoantibodies; ACPA; RF, CRP

**Introduction**

Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects 0.5%–1% of the worldwide population. It is characterized by chronic and erosive polyarthritis which in the majority of patients leads to partial disability or to permanent handicap. The exact etiology of RA is unknown but is believed to be influenced by genetic, environmental, hormonal, immunologic, and infectious factors<sup>1,2</sup>.

The diagnosis of RA based on physical exam, radiographic & laboratory tests. Unfortunately, there is no single test can confirm the diagnosis of RA. The blood tests,

erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are only markers of inflammation. RA is characteristically associated with the presence of many different autoantibodies directed against multiple autoantigens. The first discovered autoantibody in RA was rheumatoid factor (RF). It was found to react with the Fc portion of IgG antibodies. Typically, RF is of IgM isotype, but IgG and IgA may also occur. RF is found in 60–80% of RA patients and thus is fairly sensitive in the RA diagnosis. However, the specificity of RF as a diagnostic marker for RA is low since it is frequently detected in many other conditions such as connective tissue diseases<sup>3, 4</sup>. Anti-citrullinated peptide antibody (ACPA) target peptides that are post-translationally modified by conversion of arginine to citrulline, occurs primarily in patients of RA and demonstrate a much higher specificity of 95.9% for RA. In addition, ACPA seem to be a better marker of poor prognostic features of progressive joint destruction<sup>5, 6</sup>. Mannose-binding lectin (MBL) is a liver-derived acute phase protein. This C type lectin has specific binding affinity to mannose and N-acetyl glucoseamine which structurally homologous to C1q, the component of classical complement pathway. When MBL binds to the specific carbohydrate, its associated serine proteases (MBL associated serine proteases "MSAPs") become activated, leading to activation of lectin pathway of the complement system<sup>7-10</sup>.

MBL has an important role in provoking an inflammatory response and consequently has been well associated with the pathogenesis of different infectious and autoimmune diseases<sup>11,13</sup>. It has been shown that MBL binds both dimeric and polymeric IgA & activates complement<sup>14</sup>. Moreover, previous studies demonstrated that MBL can bind agalactosyl IgG & IgM including IgM RF complexes in RA patients, leading to generation of an inflammatory response<sup>13, 15</sup>. The presence of autoantibodies against MBL in serum as well as in synovial fluid from several RA patients has been reported by many studies<sup>16- 19</sup>, and they demonstrated that the anti-MBL decrease the functional activity of MBL in patients in SLE. This study aimed firstly to investigate the presence of anti-MBL autoantibodies in the sera of patients with RA and healthy controls and secondly to determine the diagnostic value of this marker in comparison with the classical RF, CRP and ACPA among RA cases.

## **Subjects and Methods**

### **Subjects**

The type of study was a case-control study which was carried out during a period from May, 2015 to May, 2016 at Al-thawra Modern General Hospital, University of Science and Technology Hospital, National Center of Central Public Health Laboratories, and Aulqi Specialized Medical Laboratories in Sana'a city. A total number of ninety-four Yemeni participants were investigated for the presence of anti-MBL autoantibodies in their sera. Forty-seven cases were clinically diagnosed with RA by a rheumatologist according to the ACR criteria<sup>20</sup>. In addition, forty-seven healthy individuals without RA were enrolled as controls. A full history was taken from each person and recorded in a predesigned questionnaire.

Five milliliter venous blood was collected from each participant into plain vacutainer tubes. The sample was allowed to clot at room temperature and centrifuged at 3500 rpm for five minutes. Serum was then separated into eppendorf tubes and stored at -20 °C till tested.

### **Autoantibody tests**

Presence of anti-MBL autoantibodies in the serum of each participant was tested using ELISA kit (Usen, Life Science Inc, USA) and the presence of ACPA was also determined by ELISA (INOVA diagnostic kits, San Diego, CA-USA). RF and CRP were measured by latex tests (Vitro Scient Co, Egypt). Cutoff was calculated from the mean + 2SD of healthy controls which equals to 390 ng/ml

### **Statistical analysis**

Statistical analysis was performed by using the Epi Info version 6 program (CDC, Atlanta, USA) for statistical significance.

### **Results**

Out of the 47 cases with RA, females represented 81%, while males represented 19% with a mean age  $43.3 \pm 14.8$  years and 49% of ages were in group  $\geq 50$  years. In addition, out of the 47 healthy controls, females represented 83%, while males represented 17% with a mean age  $43.2 \pm 14.9$  years and 47% of ages were in group  $\geq 50$  years, (Table 1).

The levels of serum anti-MBL autoantibodies were significantly increased among RA cases, in which the mean  $\pm$  SD of anti-MBL levels among RA cases was  $394 \pm 243$  ng/ml higher than the mean  $\pm$  SD of healthy controls which was  $217 \pm 173$  ng/ml with a statistical significance ( $p=0.001$ ), (Table 2). As regard the association of anti-MBL with other serological markers. The levels of serum anti-MBL autoantibodies were significantly higher among cases with RF and CRP positive than negative ( $418.4 \pm 232$ ,  $418.8 \pm 229$  ng/ml, respectively) and the other statistical variables as median, mode and ranges were also higher for cases than controls. On the other hand, the levels of anti-MBL were higher among cases with ACPA negative  $415.4 \pm 208$  ng/ml than positive  $376.8 \pm 257$  ng/ml (Table 3).

### **Discussion**

At last years, a growing evidence showed the importance of innate immune system involving lectin pathway of complement activation, of which MBL play a crucial role<sup>21-23</sup>. The low level of MBL has been apparently associated with inflammatory autoimmune diseases such as RA, SLE and other related diseases, also the deficiency of MBL can enhance the risk of infection<sup>21, 24, 25</sup>. The present study aimed firstly to investigate the presence of anti-MBL autoantibodies in the sera of patients with RA and secondly to determine the diagnostic value of this marker in comparing with the classical RF, CRP and ACPA.

The results of this study showed an obvious measurable and a higher significant presence of anti-MBL autoantibodies in the sera of enrolled RA cases (mean  $\pm$  SD =  $394 \pm 243$  ng/ml) as compared with healthy controls (mean  $\pm$  SD =  $217 \pm 173$  ng/ml) ( $p=0.001$ ). This result was similar to that reported by Gupta *et al.*<sup>26</sup> in India which showed a detectable significant presence of anti-MBL autoantibodies in the sera of RA patients as compared to the controls. This study demonstrated that the anti-MBL were more often in RA patient sera and suggested that it have a diagnostic value for RA.

When considered the association of the levels of anti-MBL with the levels of RF and CRP in this patients, the anti-MBL autoantibody levels were significantly associated with the positive cases of these markers in which the mean  $\pm$  SD of anti-MBL levels equal to  $418.4 \pm 232$  &  $418.8 \pm 229$  ng/ml, respectively. Our results were in agreeing with study by

Di Muzio *et al.*<sup>27</sup>, and disagree with study by Gupta *et al.* which reported that the levels of anti-MBL antibodies were still positive and high in negative cases of RF & CRP<sup>26</sup>.

As regard ACPA, there was no association between positive ACPA and the levels of anti-MBL autoantibodies, in which the mean $\pm$ SD of anti-MBL levels for ACPA positive cases was 376.8 $\pm$ 257 ng/ml, and for negative ACPA were 415.4 $\pm$ 208 ng/ml. To our knowledge, there is no previous study in the relation between anti-MBL levels and ACPA in RA patients that agreed or disagreed with our results.

Several studies reported that the anti-MBL autoantibodies found in different systemic autoimmune diseases as SLE and RA. These studies demonstrated that anti-MBL autoantibodies play a pathogenic role in the development of autoimmunity<sup>16-19, 28, 29</sup>. Depend on the specificity of ACPA to RA<sup>5, 6</sup>, and according to the association of anti-MBL autoantibody levels with positivity of RF and CRP but not with ACPA in our results, we can have concluded that the anti-MBL antibody levels may associated with systemic autoimmune diseases and might not exclusive to RA.

### **Conclusion and recommendations**

In our study, the levels of serum anti-MBL autoantibody were significantly increased in RA cases when compared with the healthy controls and a significant association was found between the levels of serum anti-MBL autoantibody, RF and CRP positive results, but no association with ACPA positive results. Further studies should be applied to detect the diagnostic value of serum anti-MBL autoantibody levels in RA as well as the molecular mechanism of its interaction in RA.

### **References**

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. *N Engl J Med* 2011; 365:2205-19.
2. Isaacs JD. The changing face of rheumatoid arthritis: sustained remission for all? *Nature Rev* 2010; 10:605-11
3. Waaler E. On the occurrence of a factor in human serum activating the specific agglutination of sheep red corpuscles. *Acta Pathol Microbiol Scand* 1940; 17:172-88.
4. Aletaha D, Blüml S. Therapeutic implications of autoantibodies in rheumatoid arthritis. *RMD Open*. 2016; 2(1).
5. Hayashi N, Kumagai S. Anti-cyclic citrullinated peptide antibodies and rheumatoid arthritis. *Rinsho Byori*. 2010; 58(5): 466-79.
6. Van der Linden MP, van der Woude D, Iacon-Facsinay A, *et al.* value of anti-modified citrullinated vimentin and third generation anti-cyclic citrullinated peptide compared with second generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. *Arthritis Rheum* 2009; 60:2232-41.
7. Turner MW, Hamvas RM. Mannose-binding lectin: structure, function, genetics and disease association. *Rev Immunogenet* 2000;2:305e22.
8. Ohta M, Okada M, Yamashina I, Kawasaki T. The mechanism of carbohydrate-mediated complement activation by the serum mannan-binding protein. *J Biol Chem* 1990; 265:1980e4.

9. Holmskov U, Malhotra R, Sim RB, Jensenius JC. Collectins: collagenous C-type lectins of the innate immune defense system. *Immunol Today* 1994; 15:67–74.
10. Petersen SV, Thiel S, Jensenius JC. The mannan-binding lectin pathway of complement activation: biology and disease association. *Mol Immunol.* 2001; 38: 133-49.
11. Kilpatrick DC. Mannan-binding lectin: clinical significance and applications. *Biochim Biophys Acta* 2002; 1572:401e13.
12. Eisen DP, Minchinton RM. Impact of mannose-binding lectin on susceptibility to infectious diseases. *Clin Infect Dis* 2003; 37:1496e505.
13. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. *Nat Med* 1995; 1:237e43.
14. Roos A, Bouwman LH, Munoz J, Zuiverloon T, Faber-Krol MC, Fallaux-van den Houten FC, Klar-Mohamad N, Hack CE, Tilanus MG, Daha MR: Functional characterization of the lectin pathway of complement in human serum. *Mol Immunol.* 2003, 39: 655-68. 10.1016/S0161-5890(02)00254-7.
15. Sato R, Matsushita M, Sato Y, Kasukawa R, Fujita T. Substances reactive with Mannose binding protein in sera of patients with rheumatoid arthritis. *Fukushima J Med Sci* 1997; 43:99-111
16. Seelen MA, Trouw LA, Van Der Hoorn JWA, *et al.* Autoantibodies against mannose-binding lectin in systemic lupus erythematosus. *Clin Exp Immunol.* 2003; 134: 335-43.
17. Mok MY, Jack DL, Lau CS, *et al.* Antibodies to mannose binding lectin in patients with systemic lupus erythematosus. *Lupus* 2004; 13: 522-8.
18. Takahashi R, Tsutsumi A, Ohtani K, *et al.* Anti-mannose binding lectin antibodies in sera of Japanese patients with systemic lupus erythematosus. *Clin Exp Immunol.* 2004; 136: 585-90.
19. Pradhan V, Surve P, Ghosh K. Mannose Binding Lectin (MBL) in Autoimmunity and its Role in Systemic Lupus Erythematosus. *J Assoc Physicians India.* 2010; 58:688-90.
20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, *et al.* The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum.* 1988; 31(3):315-24.
21. Heitzeneder S, Seidel M, Forster-Waldl E, Heitger A. Mannan-binding lectin deficiency - Good news, bad news, doesn't matter? *Clin Immunol* 2012; 143:22-38.
22. Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. *J Autoimmun* 2010;34: 276-86.
23. Degen SE, Jensenius JC, Thiel S. Disease-causing mutations in genes of the complement system. *Am J Hum Genet.* 2011; 88: 689-705.
24. Summerfield JA. Clinical potential of mannose-binding lectin-replacement therapy. *Biochem Soc Trans.* 2003; 31: 770-3.

25. Chalmers JD, McHugh BJ, Doherty C, Smith MP, Govan JR, Kilpatrick DC, Hill AT. Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study. *Lancet Respir Med.* 2013; 1(3):224-32.
26. Gupta B, Raghav SK, Agrawal C, Chaturvedi VP, Das RH, Das HR. Anti-MBL autoantibodies in patients with rheumatoid arthritis: prevalence and clinical significance. *J Autoimmun* 2006; 27: 125-33.
27. Di Muzio G, Perricone C, Ballanti E, *et al.* Complement system and rheumatoid arthritis: relationships with autoantibodies, serological, clinical features, and anti-TNF treatment. *Int J Immunopathol Pharmacol.* 2011; 24: 357-66.
28. Pradhan V, Mahant G, Anjali Rajadhyaksha A, *et al.* A study on anti-mannose binding lectin (anti-MBL) antibodies and serum MBL levels in Indian systemic lupus erythematosus patients. *Rheumatol Int.* 2013; 33: 1533-9.
29. Shoenfeld Y, Szyper-Kravitz M, Witte T, *et al.* Autoantibodies against protective molecules-C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus. *Ann N Y Acad Sci.* 2007; 1108: 227-39.

**Table (1):** The age and sex distribution of studied subjects for the levels of serum anti-MBL autoantibodies

| Characteristics variable | Cases n=47  |            | Controls n=47 |            | Total n=94  |            |
|--------------------------|-------------|------------|---------------|------------|-------------|------------|
|                          | No.         | %          | No.           | %          | No.         | %          |
| <b>Sex</b>               |             |            |               |            |             |            |
| female                   | 38          | 81         | 39            | 83         | 77          | 81.9       |
| male                     | 9           | 19         | 8             | 17         | 17          | 18.1       |
| <b>Total</b>             | <b>47</b>   | <b>100</b> | <b>47</b>     | <b>100</b> | <b>94</b>   | <b>100</b> |
| <b>Age groups/ Years</b> |             |            |               |            |             |            |
| <20                      | 5           | 10.6       | 4             | 8.5        | 9           | 9.6        |
| 20-29                    | 7           | 14.9       | 10            | 21.3       | 17          | 18.1       |
| 30-39                    | 5           | 10.6       | 5             | 10.6       | 10          | 10.6       |
| 40-49                    | 7           | 14.9       | 6             | 13         | 13          | 13.8       |
| ≥ 50                     | 23          | 49         | 22            | 47         | 45          | 47.9       |
| <b>Total</b>             | <b>47</b>   | <b>100</b> | <b>47</b>     | <b>100</b> | <b>94</b>   | <b>100</b> |
| Mean/Years ±SD           | 43.3 ± 14.8 |            | 43.2 ± 14.9   |            | 43.2 ± 14.8 |            |
| Min./Years               | 16          |            | 16            |            | 16          |            |
| Max./Years               | 66          |            | 66            |            | 66          |            |

**Table (2):**Titer of anti-MBL autoantibodies in both RA patients and the controls

| <b>Anti-MBL levels ng/ml</b> | <b>Cases n=47</b> | <b>Controls n=47</b> | <b>p</b> |
|------------------------------|-------------------|----------------------|----------|
| Mean± SD                     | 394 ±243          | 217±173              | <0.001   |
| Min.                         | 15                | 14                   |          |
| Max.                         | 899.6             | 781                  |          |

**Table (3):**The association between geometric mean ± SD, median, mode and range for the levels of serum anti-MBL autoantibodies and positive and negative inflammatory markers among RA cases

| <b>Inflammatory markers</b> | <b>Anti-MBL autoantibodies levels ng/ml</b> |           |       |           | <b>p</b>   |       |
|-----------------------------|---|-----------|-------|-----------|------------|-------|
|                             | Mean ±SD                                    | Median    | Mode  | Min.-Max. |            |       |
| <b>Anti-CCP</b>             | Positive                                    | 376.8±257 | 318.5 | 597.5     | 15.2 – 894 | 0.42  |
|                             | Negative                                    | 415.4±208 | 371   | 191       | 191- 781   |       |
| <b>RF</b>                   | Positive                                    | 418.4±232 | 419   | 597.5     | 29.5 – 894 | 0.02  |
|                             | Negative                                    | 300.7±265 | 232   | 15.2      | 15.2-781   |       |
| <b>CRP</b>                  | Positive                                    | 418.8±229 | 419   | 597.5     | 29.4 – 894 | 0.007 |
|                             | Negative                                    | 277.8±273 | 191   | 15.2      | 15.2 – 781 |       |